Investors
Press Releases
Recent Press Releases
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020
February 23, 2021
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020
